CRISPR-Edited Cell Lines: A New Era in Functional Oncology Research.

IF 2.8 4区医学 Q2 PHARMACOLOGY & PHARMACY

Current pharmaceutical design Pub Date : 2025-08-13 DOI:10.2174/0113816128413220250728182852

Amita Joshi Rana, Md Sadique Hussain, Ali Hanbashi, Faroq Kamli, Gyas Khan, Marwa Qadri, Saeed A Al-Qahtani, Mohammad Gayoor Khan, Sushil S Burle, Vikas Jakhmola, Gaurav Gupta

{"title":"CRISPR-Edited Cell Lines: A New Era in Functional Oncology Research.","authors":"Amita Joshi Rana, Md Sadique Hussain, Ali Hanbashi, Faroq Kamli, Gyas Khan, Marwa Qadri, Saeed A Al-Qahtani, Mohammad Gayoor Khan, Sushil S Burle, Vikas Jakhmola, Gaurav Gupta","doi":"10.2174/0113816128413220250728182852","DOIUrl":null,"url":null,"abstract":"<p><p>The use of CRISPR-Cas9 to engineer cancer cell lines has made it possible to precisely examine how cancer cells react to different drugs and therapies. Some of the key improvements are in the use of Mediator Complex Subunit 12 (MED12)-knockout cells to study cell resistance to BRAF inhibitors, CRISPR models of Epithelial-Mesenchymal Transition for breast cancer, and pharmacogenomic analysis in various cancer cell lines. CRISPR is used in immunotherapy to help Chimeric Antigen Receptor T (CAR-T) cells function better by disrupting the immune checkpoints like Programmed Cell Death Protein 1 (PD-1) and Cytotoxic T-lymphocyte- associated protein 4 (CTLA-4) and to adapt T cells to react with various antigens. As a result of these innovations, it is now possible to track how cancers like non-small cell lung cancer (NSCLC) and ovarian cancer evolve, change their epigenetic features, and find strategies to reverse their resistance. Moving forward, mixing AI analytics, single-cell multi-omics, patient-derived organoids, and CRISPR mechanisms will help improve precision oncology and speed up effective treatment planning.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical design","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113816128413220250728182852","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

The use of CRISPR-Cas9 to engineer cancer cell lines has made it possible to precisely examine how cancer cells react to different drugs and therapies. Some of the key improvements are in the use of Mediator Complex Subunit 12 (MED12)-knockout cells to study cell resistance to BRAF inhibitors, CRISPR models of Epithelial-Mesenchymal Transition for breast cancer, and pharmacogenomic analysis in various cancer cell lines. CRISPR is used in immunotherapy to help Chimeric Antigen Receptor T (CAR-T) cells function better by disrupting the immune checkpoints like Programmed Cell Death Protein 1 (PD-1) and Cytotoxic T-lymphocyte- associated protein 4 (CTLA-4) and to adapt T cells to react with various antigens. As a result of these innovations, it is now possible to track how cancers like non-small cell lung cancer (NSCLC) and ovarian cancer evolve, change their epigenetic features, and find strategies to reverse their resistance. Moving forward, mixing AI analytics, single-cell multi-omics, patient-derived organoids, and CRISPR mechanisms will help improve precision oncology and speed up effective treatment planning.

查看原文本刊更多论文

crispr编辑细胞系：功能肿瘤学研究的新时代。

利用CRISPR-Cas9来设计癌细胞系，使得精确检测癌细胞对不同药物和疗法的反应成为可能。一些关键的改进是使用介质复合物亚单位12 （MED12）敲除细胞来研究细胞对BRAF抑制剂的耐药性，乳腺癌上皮-间质转化的CRISPR模型，以及各种癌细胞系的药物基因组学分析。CRISPR用于免疫治疗，通过破坏程序性细胞死亡蛋白1 （PD-1）和细胞毒性T淋巴细胞相关蛋白4 （CTLA-4）等免疫检查点，帮助嵌合抗原受体T （CAR-T）细胞更好地发挥功能，并使T细胞适应各种抗原。由于这些创新，现在有可能追踪像非小细胞肺癌（NSCLC）和卵巢癌这样的癌症是如何进化的，改变它们的表观遗传特征，并找到逆转它们耐药性的策略。展望未来，混合人工智能分析、单细胞多组学、患者来源的类器官和CRISPR机制将有助于提高精准肿瘤学水平，加快有效的治疗计划。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current pharmaceutical design 医学-药学

CiteScore

6.30

自引率

0.00%

发文量

302

审稿时长

2 months

期刊介绍： Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field. Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.